Objective-Phospholipid transfer protein (PLTP), which binds phospholipids and facilitates their transfer between lipoproteins in plasma, plays a key role in lipoprotein remodeling, but its influence on nascent high-density lipoprotein (HDL) formation is not known. The effect of PLTP overexpression on apolipoprotein A-I (apoA-I) lipidation by primary mouse hepatocytes was investigated. Approach and Results-Overexpression of PLTP through an adenoviral vector markedly affected the amount and size of lipidated apoA-I species that were produced in hepatocytes in a dose-dependent manner, ultimately generating particles that were <7.1 nm but larger than lipid-free apoA-I. These <7.1-nm small particles generated in the presence of overexpressed PLTP were incorporated into mature HDL particles more rapidly than apoA-I both in vivo and in vitro and were less rapidly cleared from mouse plasma than lipid-free apoA-I. The <7.1-nm particles promoted both cellular cholesterol and phospholipid efflux in an ATP-binding cassette transporter A1-dependent manner, similar to apoA-I in the presence of PLTP. Lipid-free apoA-I had a greater efflux capacity in the presence of PLTP than in the absence of PLTP, suggesting that PLTP may promote ATP-binding cassette transporter A1-mediated cholesterol and phospholipid efflux.
P hospholipid transfer protein (PLTP) is a 476 residue glycoprotein with a molecular weight of 81 kDa. PLTP is expressed ubiquitously, including liver 1,2 and small intestine. 3 It is also highly expressed in macrophages 4, 5 and in atherosclerotic lesions. 6, 7 PLTP belongs to the lipopolysaccharide-binding/lipid transfer gene family that includes the lipopolysaccharide-binding protein, the neutrophil bactericidal permeability increasing protein, and cholesteryl ester transfer protein. 1 PLTP mediates the transfer of a variety of amphipathic molecules between lipoproteins, including diacylglyceride, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylglycerol, cerobroside, phosphatidylethanolamine 8 and α-tocopherol. 9 These transfer activities of PLTP have an important function in lipoprotein metabolism. The role of PLTP in atherogenesis remains uncertain, as do the underlying mechanisms. 10 An atherogenic role of PLTP was initially suggested by studies of PLTP-deficient mice. In apoB-transgenic and apoE-deficient mice, PLTP deficiency markedly decreased atherosclerosis. 11 This concept was supported by results of PLTP overexpression in mice lacking either apoE 12, 13 or the low-density lipoprotein (LDL) receptor, 14 in which overexpression of PLTP increased atherosclerosis. However, a study has suggested that expression of PLTP in macrophages is atheroprotective in low-density lipoprotein receptor (LDLR)-deficient mice with systemic PLTP deficiency. 15 The underlying mechanisms are unclear.
Plasma PLTP enhances the net transfer of phospholipids from very low-density lipoprotein (VLDL) to high-density lipoprotein (HDL) and the exchange of phospholipids between VLDL and HDL. Both the transfer and the exchange activities of PLTP are stimulated by lipoprotein lipase-induced lipolysis. 16 Phospholipid exchange between VLDL and HDL may result in net transfer of certain molecular species of phospholipid into HDL and may play a role in providing substrate for lecithin:cholesterol acyltransferase. 16 PLTP is thought to serve as an HDL conversion factor by promoting the remodeling of HDL to form larger and smaller particles. 17, 18 Triglyceride-enrichment of HDL enhances this conversion. 19 Particle fusion is responsible for the enlargement of HDL particles. 20 Concomitantly with the appearance of enlarged particles, lipid-poor apolipoprotein A-I (apoA-I) is released. 21 The mechanism(s) involved in these processes and their exact physiological relevance remain poorly understood.
A key role for PLTP in vivo is evident in PLTP-deficient mice. These mice lack plasma transfer activities for phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, sphingomyelin and have reduced cholesterol transfer activity. The reduced plasma PLTP activity results in markedly decreased plasma HDL lipid and apolipoproteins, indicating the importance of the transfer of triglyceride-rich lipoproteins surface components in maintaining HDL levels. 22 Liverspecific PLTP deficiency also significantly reduces plasma HDL and apoB-containing lipoprotein levels in mice, demonstrating the importance of hepatic PLTP in maintaining the lipoprotein levels. 23 PLTP transgenic mice that overexpress human PLTP were shown, somewhat unexpectedly, to exhibit a modest but significant decrease (30-40%) in plasma HDL cholesterol. 24 However, despite a lower HDL concentration, plasma from transgenic animals is much more efficient in preventing the accumulation of intracellular cholesterol in macrophages than plasma from wild-type (WT) mice, suggesting that PLTP contributes to HDL formation. 24 The influence of PLTP on nascent HDL formation may be one of the mechanisms to explain the conflicting results in terms of the effect of PLTP on HDL levels. A role for PLTP in HDL production is suggested by the observation that primary PLTP-deficient hepatocytes produce less nascent HDL. 23 The lipidated apoA-I secreted by PLTP-deficient hepatocytes contains less phosphatidylcholine and sphingomyelin and differs also in its phosphatidylcholine/sphingomyelin ratio and fatty acyl species composition compared with lipidated apoA-I from WT hepatocytes. 25 Several studies have demonstrated that PLTP enhances cellular cholesterol and phospholipid efflux. Treatment of cholesterol-loaded human skin fibroblasts with PLTP increases HDL binding to cells and enhances cholesterol and phospholipid efflux. 26 PLTP stabilizes ATPbinding cassette transporter A1 (ABCA1), 27 and the absence of endogenous PLTP impairs ABCA1-dependent efflux of cholesterol from lipid-loaded macrophages. 4 An amphipathic helical region of the N-terminal barrel of PLTP seems critical for ABCA1-dependent cholesterol efflux. 28 In this study, we investigated the impact of PLTP overexpression on nascent HDL formation and remodeling by primary mouse hepatocytes. Our findings indicate that PLTP exerts significant effects on apoA-I lipidation and nascent HDL biogenesis in hepatocytes by promoting both ABCA1-mediated cholesterol efflux and nascent HDL particle remodeling.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PLTP Alters Nascent HDL Formation in Hepatocytes
To investigate the effects of PLTP on nascent HDL formation in hepatocytes, primary hepatocytes were harvested 24 hours after administration of adenovirus encoding mouse phospholipid transfer protein (AdPLTP) to mice. After overnight culture, cells were treated with the liver X receptor agonist T0901317 (5 μmol/L) for 8 hours and then incubated for 16 hours with lipid-free human apoA-I (10 μg/mL). Culture medium was then characterized by nondenaturing gradient gel electrophoresis (GGE) and subsequent immunoblotting for human apoA-I ( Figure 1A) . A marked overexpression of PLTP in hepatocytes was shown by realtime polymerase chain reaction ( Figure 1B ) and Western blot analysis ( Figure 1C ). As expected, ABCA1 was expressed in hepatocytes and the liver X receptor agonist increased ABCA1 expression. The expression of PLTP in hepatocytes did not significantly alter ABCA1 expression ( Figure I was markedly changed. Overexpression of PLTP in hepatocytes affected the levels and the species of nascent HDL particles produced by hepatocytes. Although the formation of smaller nascent HDLs was reduced by PLTP, the formation of the larger HDLs was increased. These data demonstrate for the first time that PLTP affects nascent HDL biogenesis in addition to its role in mature HDL remodeling.
PLTP Remodels Nascent HDL Particles In Vitro
PLTP has been shown to remodel HDL by facilitating transfer of phospholipids between lipoprotein particles. 16 PLTP can also serve as a putative fusion factor to enlarge HDL particles. 17 However, the role of PLTP on nascent HDL remodeling is not clear. To study the effect of PLTP on preexisting nascent HDL, nascent HDL particles were generated by incubating primary hepatocytes with 5 μg/mL human 125 I-apoA-I for 24 hours. Media containing these nascent HDL particles were then incubated in vitro with PLTP containing conditioned medium produced by African green monkey kidney fibroblast-like cells (COS-7) transfected with AdPLTP. The sample was subjected to the nondenaturing GGE and visualized by autoradiography. As shown in Figure 2A , PLTP efficiently remodeled nascent HDLs in vitro in a dosedependent manner, ultimately generating small nascent HDL (sn-HDL) particles, which were <7.1 nm but slightly larger than lipid-poor apoA-I. Nascent HDL remodeling was also performed using recombinant mouse PLTP and yielded near identical results ( Figure 2B ). The size difference between sn-HDL and apoA-I was also observed on gradient GGE gels, which were run to equilibrium (3000 volt/h; Figure 
Cholesterol Efflux Capacity of PLTP-Modified Nascent HDL Particles
To determine the cellular cholesterol and phospholipid efflux capacity of the sn-HDL, baby hamster kidney cells overexpressing human ABCA1 or ATP-binding cassette transporter G1 (ABCG1) were used. Cells were labeled with 0. The sn-HDL particles promoted cellular cholesterol or phospholipid efflux in an ABCA1-dependent manner, similar to apoA-I in the presence of PLTP. ApoA-I had a greater efflux capacity in the presence of PLTP than in the absence of PLTP. PLTP alone did not promote cholesterol or phospholipid efflux ( Figure 3A and 3C). The sn-HDL served as a 15-fold better substrate for ABCA1-dependent efflux compared with ABCG1-dependent efflux. Nevertheless, the sn-HDL had a 3-fold greater capacity to promote ABCG1-dependent cholesterol efflux in the presence of PLTP than apoA-I ( Figure 3B ). Neither sn-HDL nor apoA-I in the presence or absence of PLTP promoted ABCG1-dependent phospholipid efflux, whereas HDL 3 promoted ABCG1-dependent phospholipid efflux as expected ( Figure 3D ).
Plasma Turnover of PLTP-Modified Nascent HDL Particles in Human apoA-I Transgenic Mice
Previous reports have indicated that different sized nascent HDLs exhibit different plasma clearance rates. 29 We next examined whether plasma clearance of sn-HDL in vivo differs from apoA-I. A tracer of 1.4 μg 125 I-sn-HDL (≈1×10 6 cpm in 100 μL) in cell medium was injected via tail vein into a C57BL/6-Tg (APOA1) 1Rub/J mouse. This strain of mice was used because HDL in these animals contains predominantly human A-I and because apoA-I from human and mouse interacts differently with HDL. An equivalent amount of 125 I-apoA-I, preincubated with the same amount of PLTPcontaining medium that was used to generate sn-HDL, was studied for comparison. At the selected intervals after tracer injection (3 minutes to 4 hours), plasma samples were collected and 125 I determined. At 4 hours after tracer injection, the mice were humanely killed, and livers and kidneys were collected and radioassayed.
It is evident from the plasma clearance curves that clearance of 125 I-sn-HDL was significantly slower (≈3-fold) compared with lipid-free apoA-I ( Figure 4A ). The times taken to clear 50% of the injected doses of sn-HDL and apoA-I were 0.97±0.014 and 0.35±0.017 hours (P<0.0001), respectively. It is also evident that clearance of both ligands is biphasic with more rapid clearance of apoA-I than sn-HDL during both phases. Clearance of HDL apoA-I has been best described using a 2 pool model with a rapid initial phase being associated with an equilibration of ligand between the vascular and extravascular pools. An accurate determination of the fractional clearance rates of the 2 ligands will require a more extensive data set than shown in Figure 4 . Analysis of plasma samples by nondenaturing GGE demonstrated that injected 125 I-sn-HDL was rapidly incorporated into larger HDL-sized particles and more rapidly than 125 I-apoA-I ( Figure 4B ). Interestingly, incorporated 125 I-sn-HDL protein appeared to be less rapidly cleared from plasma than HDL-associated 125 I-apoA-I. After 4 hours of tracer injection, significant amounts of 125 I-sn-HDL protein remained associated with HDL-sized particles, whereas the majority of 125 I-apoA-I had been cleared from such particles. A more efficient incorporation of sn-HDL into HDL particles that have a slower clearance rate may contribute to its reduced plasma clearance compared with apoA-I. In contrast, 125 I-apoA-I rapidly disappears from the unlipidated and the HDL-sized fraction. This suggests that the 125 I-apoA-I association with HDL may be less firmly bound than in the case of 125 I-sn-HDL and might therefore contribute to its rapid clearance from plasma.
Because lipid-free and lipid-poor apoA-I has been shown to clear more rapidly from plasma than HDL, particularly through the kidney, the efficient association of sn-HDL with HDL in the plasma might therefore reduce its clearance rate as a result of reduced clearance by the kidney. To identify the possible tissue sites of clearance of apoA-I, livers and kidneys were removed from recipient mice 4 hours after tracer injection and radiolabel content was determined as percentage of injected tracer. As shown in Figure IVA and IVB in the online-only Data Supplement, 125 I accumulation, in the kidney but not in the liver, is greater for 125 I-apoA-I than 125 I-sn-HDL despite a lower plasma concentration of 125 I-apoA-I. This suggests that reduced clearance of 125 I-sn-HDL in the kidney may contribute to its slower rate of clearance compared with apoA-I. To substantiate this possibility, additional studies using a nondegradable-modified apoA-I are required to quantify rates of tissue uptake of these ligands.
Remodeling of PLTP-Modified Nascent HDL Particles In Vitro
Based on the data presented in Figure 4B , sn-HDL seems to associate with circulating HDL in vivo. To examine the ability of sn-HDL to incorporate into HDL in vitro, 50 ng in 10 μL of cell medium containing 125 I-sn-HDL or 125 I-apoA-I, pretreated with equal volume of PLTP (15.4 pmole/μL/h), was incubated with 15 μg of unlabeled HDL 2b or HDL 3 for indicated times at 37°C ( Figure 5A and 5B) . The reaction was analyzed by nondenaturing GGE and visualized by autoradiography.
The 125 I-sn-HDL was rapidly associated with HDL 2b or HDL 3 , as indicated by the migration of the vast majority of the radiolabel at a size corresponding to HDL after 5-minute incubation. The association of 125 I-sn-HDL to mature HDL particles seemed to be more complete and less reversible with time compared with 125 I-apoA-I. After 4-hour incubation, the majority of the 125 I-sn-HDL remained associated with HDL 2b or HDL 3 (Figure 5A and 5B) , whereas almost half of the apoA-I was dissociated from HDL 2b (Figure 5A ). In the case Figure 5B ). These results indicated that compared with lipid-free apoA-I, the apoA-I of sn-HDL was either more readily incorporated into HDL or more effectively exchanged with apoA-I in HDL.
Discussion
PLTP plays a key role in HDL remodeling and function during physiological and pathophysiological conditions. 10 Whether PLTP modulates the process of nascent HDL formation remains to be clarified. Because liver is the primary site for HDL biogenesis and a major source of PLTP expression, we investigated the effects of PLTP overexpression on nascent HDL formation and nascent HDL remodeling in primary mouse hepatocytes. We observed that hepatocyte overexpression of PLTP markedly affected the amount and size of lipidated apoA-I species that were produced, confirming a significant role of PLTP on HDL biogenesis and providing new insight into how PLTP influences HDL metabolism. A role for PLTP in HDL production is evident by the observation that PLTP-deficient hepatocytes produced less nascent HDL. 23 Conversely, recombinant PLTP promoted HDL formation in hepatocytes. 23 However, how PLTP affects HDL production is not clear. We observed that PLTP overexpression in hepatocytes changed the spectrum of nascent HDL particles produced by hepatocytes. The formation of the larger HDL particles was increased by PLTP overexpression in hepatocytes ( Figure 1A) . These results demonstrated that PLTP promoted the enlargement of nascent HDL particles. PLTP has been reported to enlarge mature HDL particles by inducing particle fusion. Such enlarged particles were not stable when injected intravenously into mice being rapidly cleared from the circulation. 20, 21 The mechanism whereby PLTP produces larger nascent HDLs is not known but may, as for mature HDL remodeling, involve particle fusion.
We showed that PLTP altered nascent HDL formation in hepatocytes at least partly by remodeling lipidated apoA-I species after they were formed. The ability of PLTP to remodel nascent HDL particles was previously investigated by incubating nascent HDL particles with WT or PLTP-deficient mouse plasma. 29 Incubation of pre-β HDLs in control plasma resulted in remodeling of pre-β1 and pre-β2 particles to medium-sized HDL (8-10 nm) and remodeling of pre-β3 and pre-β4 to small HDL (7-8 nm) . Remodeling of all nascent pre-β HDL particles was significantly decreased in PLTP-deficient plasma compared with WT control plasma, suggesting that PLTP is necessary for remodeling of nascent pre-β HDL. 29 To further examine the effects of PLTP on nascent HDL particle remodeling, we incubated the nascent HDL particles generated from control hepatocytes with PLTP in vitro. PLTP in cellconditioned medium obtained from overexpressing COS cells and recombinant PLTP yielded similar results. As shown in Figure 2 , PLTP was able to modulate nascent HDL particles in vitro in a dose-dependent manner, ultimately generating particles that were <7.1 nm, but larger than apoA-I, from larger nascent HDLs. PLTP has been reported to release lipid-poor apoA-I from mature HDL particles during HDL remodeling process. 21 Our results demonstrated that PLTP is capable of remodeling nascent HDL particles and releasing small apoA-I species (sn-HDL) from nascent HDLs.
To examine whether PLTP modulated an early step in nascent HDL formation, namely cellular cholesterol efflux, baby hamster kidney cells overexpressing human ABCA1 or ABCG1 were examined. PLTP did promote apoA-Iinduced cholesterol efflux in an ABCA1-dependent manner ( Figure 3A) . These results demonstrated that PLTP is capable of enhancing apoA-I lipidation by ABCA1. This is in line with previous studies that macrophage foam cells from PLTPdeficient mice released less cholesterol to lipid-free apoA-I and to HDL than did the corresponding WT foam cells, 4 suggesting the involvement of PLTP in cellular cholesterol efflux. It has also been reported that PLTP interaction with ABCA1 stabilizes the transporter, suggesting the significance of PLTP in ABCA1-mediated cholesterol efflux. 27, 28 It is possible that PLTP may function through its ability to transfer phospholipids and this notion is in line with our results showing that PLTP does promote the efflux of phospholipids to apoA-I, in addition to cholesterol efflux.
To examine the possible physiological effects of PLTP modification on nascent HDL function, we determined the efflux capacity of sn-HDL that is generated by the action of PLTP on nascent HDLs. As shown in Figure 3A , these particles promoted cellular cholesterol efflux in an ABCA1dependent manner to similar extent as apoA-I. The cholesterol efflux induced by PLTP-modified particles was more ABCA1 dependent than ABCG1 dependent; however, sn-HDL had a greater capacity to promote ABCG1-dependent cholesterol efflux than apoA-I ( Figure 3B ). ABCA1 was recognized as the principal molecule involved in cholesterol efflux to apoA-I from macrophage foam cells. 30 In addition to ABCA1, another ATP-binding cassette transporter, ABCG1, has been shown to contribute to cholesterol efflux to HDL from macrophages. 31 A synergistic relationship between ABCA1 and ABCG1 in promoting cholesterol efflux has been proposed. 32, 33 The nascent HDL particles generated through ABCA1 action were shown to function as efficient acceptors for ABCG1-mediated cholesterol efflux. 32, 33 In the present study, we demonstrated that PLTP-modified nascent HDL particles had a greater capacity to promote ABCG1-dependent cholesterol efflux than apoA-I, suggesting a role of PLTP in the synergistic effect of ABCA1 and ABCG1 in promoting cellular cholesterol efflux. The functional properties of sn-HDL in mediating cholesterol efflux through the different cholesterol transporters are consistent with a minimal but significant lipidation of apoA-I in sn-HDL. Together with increased size of sn-HDL and its altered capacity to associate with HDL, these results strongly support a lipidated state of apoA-I in sn-HDL.
To study the possible metabolic fate of these small PLTPgenerated species in vivo, we injected 125 I-labeled sn-HDL into human apoA-I transgenic mice to assess the plasma turnover rate of these small particles in comparison with lipidfree apoA-I. As shown in Figure 4 , in the presence of PLTP, the plasma clearance of sn-HDL was significantly slower compared with that of apoA-I. We also demonstrated that these small particles were rapidly remodeled to mature HDLsized particles both in vivo and in plasma ex vivo, likely by fusion with preexisting HDL (Figures 4 and 5) . Such remodeling of sn-HDL occurred more effectively than the remodeling of lipid-free apoA-I. Remodeling of sn-HDL resulted in particles that appeared to be less rapidly cleared in vivo than lipid-free apoA-I or particles generated from lipid-free apoA-I. It is possible that the remodeling observed involved apoA-I exchange between sn-HDL and preexisting HDL rather than a net transfer of sn-HDL onto plasma HDL. Perhaps more likely, given the relatively small size and predicted low lipid content of sn-HDL, remodeling involved the displacement of apoA-I from HDL by sn-HDL. It is likely that the structure and composition of nascent HDL particles, as well as their interaction with plasma factors, including PLTP, have a significant impact on the extent to which apoA-I is liberated from HDL. Overall, the results do provide clear evidence that sn-HDL is subject to increased remodeling and decreased plasma turnover compared with lipid-poor apoA-I. It is generally accepted that nascent HDLs acquire unesterified cholesterol and associate with lecithin:cholesterol acyltransferase, leading to cholesterol esterification and their conversion to mature HDL. 34 Our studies provide evidence for another mechanism by which nascent HDLs can enter the mature HDL pool that is enhanced by PLTP-mediated particle remodeling.
Our findings suggest that PLTP exerts significant effects on apoA-I lipidation and nascent HDL biogenesis in hepatocytes by promoting ABCA1-dependent cholesterol efflux and the remodeling of nascent HDL particles.
